A detailed history of Harbor Capital Advisors, Inc. transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 133,707 shares of BCYC stock, worth $2.74 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
133,707
Previous 55,289 141.83%
Holding current value
$2.74 Million
Previous $1.12 Million 170.42%
% of portfolio
0.13%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$19.58 - $27.24 $1.54 Million - $2.14 Million
78,418 Added 141.83%
133,707 $3.03 Million
Q2 2024

Jul 09, 2024

BUY
$20.02 - $24.69 $236,416 - $291,564
11,809 Added 27.16%
55,289 $1.12 Million
Q1 2024

May 13, 2024

BUY
$16.75 - $26.1 $281,266 - $438,271
16,792 Added 62.92%
43,480 $1.08 Million
Q4 2023

Jan 08, 2024

BUY
$13.29 - $22.2 $32,932 - $55,011
2,478 Added 10.24%
26,688 $482,000
Q3 2023

Oct 20, 2023

BUY
$19.9 - $26.25 $62,983 - $83,081
3,165 Added 15.04%
24,210 $486,000
Q2 2023

Jul 11, 2023

BUY
$18.95 - $28.67 $36,251 - $54,845
1,913 Added 10.0%
21,045 $537,000
Q1 2023

Apr 26, 2023

SELL
$20.02 - $31.37 $100,400 - $157,320
-5,015 Reduced 20.77%
19,132 $406,000
Q4 2022

Jan 20, 2023

SELL
$20.37 - $32.9 $438,362 - $708,008
-21,520 Reduced 47.12%
24,147 $0
Q3 2022

Oct 28, 2022

SELL
$17.49 - $28.44 $93,746 - $152,438
-5,360 Reduced 10.5%
45,667 $1.06 Million
Q2 2022

Jul 26, 2022

BUY
$12.95 - $46.99 $286,000 - $1.04 Million
22,085 Added 76.31%
51,027 $856,000
Q1 2022

Apr 28, 2022

SELL
$40.12 - $59.5 $226,998 - $336,651
-5,658 Reduced 16.35%
28,942 $1.27 Million
Q4 2021

Feb 04, 2022

BUY
$41.7 - $61.14 $1.44 Million - $2.12 Million
34,600 New
34,600 $2.11 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $607M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.